"Ifosfamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
| Descriptor ID |
D007069
|
| MeSH Number(s) |
D02.455.526.728.650.730.243.250 D02.705.672.500.243.250 D03.383.533.500
|
| Concept/Terms |
Ifosfamide- Ifosfamide
- Isofosfamide
- Isophosphamide
- Iphosphamide
- Iso-Endoxan
- Iso Endoxan
NSC-109,724- NSC-109,724
- NSC 109,724
- NSC109,724
- NSC-109724
- NSC 109724
- NSC109724
|
Below are MeSH descriptors whose meaning is more general than "Ifosfamide".
Below are MeSH descriptors whose meaning is more specific than "Ifosfamide".
This graph shows the total number of publications written about "Ifosfamide" by people in this website by year, and whether "Ifosfamide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ifosfamide" by people in Profiles.
-
Hattinger CM, Michelacci F, Sella F, Magagnoli G, Benini S, Gambarotti M, Palmerini E, Picci P, Serra M, Ferrari S. Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy. Histopathology. 2015 Sep; 67(3):338-47.
-
Taupin D, Racela R, Friedman D. Ifosfamide chemotherapy and nonconvulsive status epilepticus: case report and review of the literature. Clin EEG Neurosci. 2014 Jul; 45(3):222-5.
-
Moretti VM, Crawford EA, Staddon AP, Lackman RD, Ogilvie CM. Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy. Am J Clin Oncol. 2011 Aug; 34(4):417-21.
-
Fanale M, Fayad L, Pro B, Samaniego F, Liboon MJ, Nunez C, Horowitz S, Anderlini P, Popat U, Ji Y, Kwak LW, Younes A. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol. 2011 Jul; 154(2):284-6.
-
Ogilvie CM, Crawford EA, Slotcavage RL, King JJ, Lackman RD, Hartner L, Staddon AP. Treatment of adult rhabdomyosarcoma. Am J Clin Oncol. 2010 Apr; 33(2):128-31.
-
Serra M, Scotlandi K, Reverter-Branchat G, Ferrari S, Manara MC, Benini S, Incaprera M, Bertoni F, Mercuri M, Briccoli A, Bacci G, Picci P. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol. 2003 Feb 01; 21(3):536-42.
-
Weiss AJ, Lackman RD. A comparison of human G-Csf and human Gm-Csf given concurrently with anti-cancer chemotherapy. Oncol Rep. 2002 Sep-Oct; 9(5):945-50.